Altamira Therapeutics Ltd.: rnd_expense
| Value | {"unit": "CHF", "value": 3325281, "concept": "us-gaap:ResearchAndDevelopmentExpense"} |
|---|---|
| Period | 2019-01-01 – 2019-12-31 |
| Status | current |
| Entity | Altamira Therapeutics Ltd. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T16:24:22.861909+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/e0708c89-1850-4d45-8c29-17709d5c84ad
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001213900-20-009292Retrieved: 2026-08-19T16:24:22.861909+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001601936/rnd-expense/2019-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/e0708c89-1850-4d45-8c29-17709d5c84ad
History
- no predecessors — first report